SELLAS Life Sciences (SLS) Divestments (2015 - 2016)
SELLAS Life Sciences' (SLS) quarterly Divestments came in at -$1.0 million in Q1 2016, down 110.0% year-on-year from $10.5 million in Q2 2015, and down 109.31% on a QoQ basis from $11.3 million in Q4 2015.
SELLAS Life Sciences (SLS) Divestments (2015 - 2016) Analysis & Trends
SELLAS Life Sciences (SLS) has 2 years of Divestments data on file, last reported at -$1.0 million in Q1 2016.
- On a quarterly basis, Divestments fell 110.0% year-over-year to -$1.0 million in Q1 2016; TTM through Dec 2016 was -$1.0 million, a 109.77% decrease from a year earlier, with the FY2016 full-year figure at -$1.0 million, down 109.77% from the prior year.
- Divestments for Q1 2016 stood at -$1.0 million, down from $11.3 million in the prior quarter.
- Over the last five years, Divestments for SLS reached as high as $11.3 million in Q4 2015 and fell as low as -$1.0 million in Q1 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Divestments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -32.58 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | SELLAS Life Sciences | 1.96 Bn | 1.96 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2016 | -1.05 Mn |
| Dec 31, 2015 | 11.28 Mn |
| Jun 30, 2015 | -34,000.00 |
| Mar 31, 2015 | -500,000.00 |